Sequential rituximab and omalizumab for the treatment of eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome)
| Autor: | Juan-Carlos Bravo, Fabio Bonilla-Abadía, Carlos A. Cañas, Gabriel J. Tobón, David Aguirre-Valencia, Iván Posso-Osorio |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
medicine.medical_specialty
Adolescent medicine.medical_treatment Omalizumab Churg-Strauss Syndrome 03 medical and health sciences 0302 clinical medicine Rheumatology immune system diseases hemic and lymphatic diseases Internal medicine Eosinophilic medicine Humans 030212 general & internal medicine Rhinitis Asthma 030203 arthritis & rheumatology Bronchial Spasm business.industry General Medicine medicine.disease Dermatology respiratory tract diseases Treatment Outcome Gastric Mucosa Immunology Female Rituximab Plasmapheresis Granulomatosis with polyangiitis Vasculitis business medicine.drug |
| Zdroj: | Clinical Rheumatology. 36:2159-2162 |
| ISSN: | 1434-9949 0770-3198 |
| DOI: | 10.1007/s10067-017-3780-9 |
| Popis: | Eosinophilic granulomatosis with polyangiitis (EGPA), formerly known as Churg-Strauss syndrome (CSS), is a small vessel vasculitis associated with eosinophilia and asthma. Clinical manifestations commonly seen in patients presenting with EGPA range from upper airway and lung involvement to neurological, cardiac, cutaneous, and renal manifestations. Treatment for severe presentations includes steroids, cyclophosphamide, plasmapheresis, and recently, rituximab. Rituximab is associated with a good response in the treatment of vasculitis, but a variable response for the control of allergic symptoms. Here, we report a 16-year-old female patient with severe EGPA (gastrointestinal and cutaneous vasculitis, rhinitis and asthma) refractory to conventional treatment. She was treated with rituximab, which enabled rapid control of the vasculitis component of the disease, but there was no response to rhinitis and asthma. Additionally, she developed severe bronchospasm during rituximab infusion. Sequential rituximab and omalizumab were initiated, leading to remission of all manifestations of vasculitis, rhinitis, and asthma, in addition to bronchospasm related to rituximab infusion. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink